Observation
Copyright ©2009 Baishideng.
World J Gastrointest Oncol. Oct 15, 2009; 1(1): 21-25
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.21
Table 1 Use of aspirin in average risk subjects and colonic neoplasia risk reduction
StudynAspirin dose (mg/AD)Study duration (yr)Relative risk reduction (95% CI)
Thun et al[13]622 424100 mg3≥ 10.58 (0.36-0.93)1
0.61 (0.38-0.97)2
Gann et al[14]2207132551.15 (0.80-1.65)1
Cook et al[15]39876100100.97 (0.77-1.24)2
Stürmer et al[16]22071325121.03 (0.83-1.28)
Giovannucci et al[17]4790032540.54 (0.34-0.84)1
Paganini-Hill et al[18]139793257-101.38 (NR)1
Chan et al[19]89446100100.62 (0.44-0.86)2
Friis et al[20]2947032560.9 (0.70-1.10)1
García-Rodríguez et al[21]12005325> 20.9 (0.8-1.1)
Reeves et al[22]845100> 50.79 (0.46-1.36)2
Juarranz et al[23]502325NR0.32 (0.09-1.10)
La Vecchia et al[24]324832550.7 (0.50-1.00)
Kune et al[25]1442325NR0.57 (0.41-0.79)
Suh et al[26]270432560.33 (0.15-0.72)
Slattery et al[27]3051325> 50.7 (0.6-0.8)
Table 2 Role of aspirin in colorectal neoplasia risk among patients with past tumour
TrialsnAspirin doseDuration (yr)Relative risk (95% CI)
Baron et al[28]112181/325 mg10.96 (0.81-1.13)
Benamouzig et al[29]272160/300 mg10.82 (0.7-0.95)
Greenberg et al[30]86440.52 (0.31-0.89)
PPSG[31]1905< 325 mg40.82 (0.65-1.02)
> 325 mg0.54 (0.3-0.96)
Sandler et al[32]492> 15 tab/month50.84 (0.5-1.43)
Breuer-Katschinski et al[33]442> 4 tab/week< 50.91 (0.32-2.64)
> 50.09 (0.01-0.82)
Table 3 Colorectal cancer and the potential carcinogenic role of various factors
CRC category (% diagnosed with CRC)Intervention strategies
Sporadic CRC (75%)Screening Programmes
Detection and removal of polyps (age > 50 yr)
Role of chemoprevention
NSAIDs/Aspirin
5-aminosalicylate
Dietary and lifestyle factors
Good: low protein, high fibre, low fat, micronutrients, exercise
Bad: alcohol, tobacco, obesity
Familial syndromes + miscellaneous (25%)Screening colonoscopy
Other: Aspirin and NSAIDs, 5-ASA